X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TFF VORI (voriconazole) is a next-generation, direct-to-lung, inhaled dry powder formulation of voriconazole for the treatment of invasive pulmonary aspergillosis & allergic bronchopulmonary aspergillosis.
Lead Product(s): Voriconazole
Therapeutic Area: Infections and Infectious Diseases Product Name: TFF VORI
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2024
Details:
TFF TAC (tacrolimus) is a next-generation, direct-to-lung, inhaled dry powder formulation of tacrolimus for the treatment and prevention of prophylaxis of organ rejection in lung transplant.
Lead Product(s): Tacrolimus
Therapeutic Area: Immunology Product Name: TFF TAC
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2024
Details:
TFF TAC (tacrolimus) is a next-generation, direct-to-lung, inhaled dry powder formulation of tacrolimus for the treatment and prevention of prophylaxis of organ rejection in lung transplant.
Lead Product(s): Tacrolimus
Therapeutic Area: Immunology Product Name: TFF-TAC
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2023
Details:
TFF VORI (voriconazole inhalation powder) is a next-generation, direct-to-lung, inhaled dry powder formulation of voriconazole in development for the treatment and prevention of invasive pulmonary aspergillosis (IPA), a severe fungal pulmonary disease.
Lead Product(s): Voriconazole
Therapeutic Area: Infections and Infectious Diseases Product Name: TFF Vori
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 31, 2023
Details:
The net proceeds will be used to continue development of a shelf-stable dry powder formulation of a novel, pan-flu multivariant mucosal universal influenza vaccine using the Company’s thin film freezing technology.
Lead Product(s): Universal Influenza Virus Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: National Institute of Allergy and Infectious Diseases
Deal Size: $2.9 million Upfront Cash: Undisclosed
Deal Type: Funding June 26, 2023
Details:
The agreement aims to develop respirable, dry powder formulations of high molecular weight hyaluronan for treating or preventing respiratory diseases with a primary focus on COPD and viral respiratory diseases caused by SARS-CoV-2, influenza virus, and RSV.
Lead Product(s): Sodium Hyaluronate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: National Institute of Environmental Health Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 04, 2023
Details:
TFF Pharmaceuticals intends to use the net proceeds from the offering for clinical trials, research and development, working capital and general corporate purposes.
Lead Product(s): Voriconazole
Therapeutic Area: Infections and Infectious Diseases Product Name: TFF VORI
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: JonesTrading Institutional Services
Deal Size: $12.3 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 29, 2022
Details:
The development of an effective intranasal vaccine has numerous potential advantages over conventional, subcutaneous or intramuscular-based delivery.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Aptar Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 03, 2022
Details:
TFF VORI (voriconazole) is a next-generation, direct-to-lung, inhaled dry powder formulation of voriconazole for the treatment and prevention of Invasive Pulmonary Aspergillosis (IPA).
Lead Product(s): Voriconazole
Therapeutic Area: Infections and Infectious Diseases Product Name: TFF VORI
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2022
Details:
TFF VORI (voriconazole) is a next-generation, direct-to-lung, inhaled dry powder formulation of voriconazole for the treatment and prevention of Invasive Pulmonary Aspergillosis (IPA).
Lead Product(s): Voriconazole
Therapeutic Area: Infections and Infectious Diseases Product Name: TFF VORI
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
